IL174445A - Substituted isoquinolinone derivatives and pharmaceutical compositions containing the same and uses thereof - Google Patents

Substituted isoquinolinone derivatives and pharmaceutical compositions containing the same and uses thereof

Info

Publication number
IL174445A
IL174445A IL174445A IL17444506A IL174445A IL 174445 A IL174445 A IL 174445A IL 174445 A IL174445 A IL 174445A IL 17444506 A IL17444506 A IL 17444506A IL 174445 A IL174445 A IL 174445A
Authority
IL
Israel
Prior art keywords
alkyl
fluoro
cycloalkyl
group
compound
Prior art date
Application number
IL174445A
Other languages
English (en)
Other versions
IL174445A0 (en
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of IL174445A0 publication Critical patent/IL174445A0/en
Publication of IL174445A publication Critical patent/IL174445A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL174445A 2003-10-03 2006-03-21 Substituted isoquinolinone derivatives and pharmaceutical compositions containing the same and uses thereof IL174445A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50840203P 2003-10-03 2003-10-03
PCT/US2004/032104 WO2005035520A1 (en) 2003-10-03 2004-09-29 Substituted isoquinolinones

Publications (2)

Publication Number Publication Date
IL174445A0 IL174445A0 (en) 2006-08-01
IL174445A true IL174445A (en) 2012-02-29

Family

ID=34434908

Family Applications (1)

Application Number Title Priority Date Filing Date
IL174445A IL174445A (en) 2003-10-03 2006-03-21 Substituted isoquinolinone derivatives and pharmaceutical compositions containing the same and uses thereof

Country Status (10)

Country Link
US (1) US7294635B2 (https=)
EP (1) EP1667989A4 (https=)
JP (1) JP4879745B2 (https=)
KR (1) KR20060113699A (https=)
CN (1) CN1863789B (https=)
AU (1) AU2004279809B2 (https=)
CA (1) CA2539882A1 (https=)
IL (1) IL174445A (https=)
MX (1) MXPA06003625A (https=)
WO (1) WO2005035520A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031565B (zh) * 2004-09-29 2010-09-29 博尔托拉制药公司 取代的2h-1,3-苯并噁嗪-4(3h)-酮
RU2008101924A (ru) * 2005-07-13 2009-08-20 Астразенека Аб (Se) Новые аналоги пиридина
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
TW200811133A (en) * 2006-07-04 2008-03-01 Astrazeneca Ab New pyridine analogues III 334
US20080009523A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab New Pyridine Analogues IV
US20080032992A1 (en) * 2006-07-04 2008-02-07 Astrazeneca Ab New Pyridine Analogues V
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
ES2475193T3 (es) 2007-01-22 2014-07-10 Gtx, Inc. Agentes de unión al receptor nuclear
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
TW200911755A (en) 2007-04-19 2009-03-16 Astellas Pharma Inc Bicyclic heterocyclic compounds
MX2009011755A (es) * 2007-05-02 2010-02-12 Portola Pharm Inc Terapia de combinacion con un compuesto que actua como un inhibidor del receptor adp de plaquetas.
US20090018166A1 (en) * 2007-07-13 2009-01-15 Astrazeneca Ab New Pyridine Analogues X 161
CN103739547B (zh) * 2014-01-03 2015-09-02 沈阳药科大学 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
ES2718175T3 (es) * 2014-12-02 2019-06-28 Lilly Co Eli Compuestos de 1-oxo-1,2-dihidroisoquinolin-7-il-(tiofen-2-il-5-sustituido)-sulfonamida, formulaciones que contienen esos compuestos, y su uso como inhibidores de AICARFT en el tratamiento de cánceres
SI3259253T1 (sl) 2015-02-16 2020-07-31 The University Of Queensland Sulfonilsečnine in sorodne spojine ter njihova uporaba
NZ760129A (en) 2017-07-07 2025-12-19 Inflazome Ltd Novel sulfonamide carboxamide compounds
UY37848A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
MA49903A (fr) 2017-08-15 2020-06-24 Inflazome Ltd Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
TWI721623B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
TW202136261A (zh) 2018-10-31 2021-10-01 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847925A (en) * 1971-07-15 1974-11-12 En Nom Collectif Science Et Ci Benzenesulfonyl semicarbazides
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
JP2002509152A (ja) 1998-01-15 2002-03-26 シーオーアール セラピューティクス インコーポレイテッド 血小板adp受容体阻害剤
DK1257550T3 (da) * 2000-02-04 2006-03-27 Portola Pharm Inc Blodplade-ADP-receptor-inhibitor
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors

Also Published As

Publication number Publication date
WO2005035520A1 (en) 2005-04-21
EP1667989A4 (en) 2008-08-20
MXPA06003625A (es) 2006-08-11
CN1863789B (zh) 2010-06-09
CN1863789A (zh) 2006-11-15
JP4879745B2 (ja) 2012-02-22
US7294635B2 (en) 2007-11-13
IL174445A0 (en) 2006-08-01
US20050113399A1 (en) 2005-05-26
EP1667989A1 (en) 2006-06-14
CA2539882A1 (en) 2005-04-21
JP2007507519A (ja) 2007-03-29
AU2004279809B2 (en) 2010-07-15
AU2004279809A1 (en) 2005-04-21
KR20060113699A (ko) 2006-11-02

Similar Documents

Publication Publication Date Title
AU2004279809B2 (en) Substituted isoquinolinones
AU2004278030B2 (en) 2,4-Dioxo-3-quinazolinylaryl sulfonylureas
US7205296B2 (en) Substituted 2H-1,3-benzoxazin-4(3H)-ones
US8680139B2 (en) Anti-neoplastic compounds, compositions and methods
JP6281984B2 (ja) 1,2,4−トリアジン−6−カルボキサミドキナーゼ阻害剤
WO2003011872A1 (en) Platelet adp receptor inhibitors
JPWO2006057270A1 (ja) 含窒素3環化合物
EP2094272B1 (en) Nitrogen containing substituted heterocycles as platelet adp receptor inhibitors
HK1093973B (en) 2,4-dioxo-3-quinazolinylaryl sulfonylureas
HK1111414B (en) Substituted 2h-1,3-benzoxazin-4(3h)-ones
HK1131058B (en) Nitrogen containing substituted heterocycles as platelet adp receptor inhibitors
HK1209277B (en) 1,2,4-triazine-6-carboxamide kinase inhibitors

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees